首页 > 最新文献

Biological & pharmaceutical bulletin最新文献

英文 中文
The Association between Transformation Ability and Antimicrobial Resistant Potential in Haemophilus influenzae. 流感嗜血杆菌的转化能力与抗微生物耐药性之间的关系。
IF 2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 Epub Date: 2023-10-25 DOI: 10.1248/bpb.b23-00583
Emi Tanaka, Takeaki Wajima, Ruri Ota, Kei-Ichi Uchiya

The prevalence of quinolone low-susceptible Haemophilus influenzae has increased in Japan. Low quinolone susceptibility is caused by point mutations in target genes; however, it can also be caused by horizontal gene transfer via natural transformation. In this study, we examined whether this horizontal gene transfer could be associated with resistance to not only quinolones but also other antimicrobial agents. Horizontal transfer ability was quantified using the experimental transfer assay method for low quinolone susceptibility. Further, the association between horizontal transfer ability and resistance to β-lactams, the first-choice drugs for H. influenzae infection, was investigated. The transformation efficiency of 50 clinical isolates varied widely, ranging from 102 to 106 colony forming unit (CFU) of the colonies obtained by horizontal transfer assay. Efficiency was associated with β-lactam resistance caused by ftsI mutations, indicating that strains with high horizontal transfer ability acquired quinolone low-susceptibility as well as β-lactam resistance more easily. Strains with high transformation efficiency increased the transcript level of comA, suggesting that enhanced com operon was associated with a high DNA uptake ability. Overall, this study revealed that the transformation ability of H. influenzae was associated with multiple antimicrobial resistance. Increase in the number of strains with high horizontal transformation ability has raised concerns regarding the rapid spread of antimicrobial-resistant H. influenzae.

日本喹诺酮类低感流感嗜血杆菌的流行率有所上升。喹诺酮类药物的低易感性是由靶基因的点突变引起的;然而,它也可能是由通过自然转化的水平基因转移引起的。在这项研究中,我们检测了这种水平基因转移是否不仅与喹诺酮类药物的耐药性有关,还与其他抗菌药物的耐药性相关。使用低喹诺酮类药物敏感性的实验转移测定方法对水平转移能力进行定量。此外,还研究了水平转移能力与对治疗流感嗜血杆菌感染的首选药物β-内酰胺类药物的耐药性之间的关系。50个临床分离株的转化效率差异很大,通过水平转移测定获得的菌落的转化效率在102-106CFU之间。效率与ftsI突变引起的β-内酰胺耐药性有关,表明具有高水平转移能力的菌株更容易获得喹诺酮类低易感性和β-内胺耐药性。具有高转化效率的菌株增加了comA的转录水平,这表明增强的com操纵子与高DNA摄取能力有关。总的来说,这项研究表明流感嗜血杆菌的转化能力与多种抗微生物耐药性有关。具有高水平转化能力的菌株数量的增加引起了人们对耐药性流感嗜血杆菌快速传播的担忧。
{"title":"The Association between Transformation Ability and Antimicrobial Resistant Potential in Haemophilus influenzae.","authors":"Emi Tanaka, Takeaki Wajima, Ruri Ota, Kei-Ichi Uchiya","doi":"10.1248/bpb.b23-00583","DOIUrl":"10.1248/bpb.b23-00583","url":null,"abstract":"<p><p>The prevalence of quinolone low-susceptible Haemophilus influenzae has increased in Japan. Low quinolone susceptibility is caused by point mutations in target genes; however, it can also be caused by horizontal gene transfer via natural transformation. In this study, we examined whether this horizontal gene transfer could be associated with resistance to not only quinolones but also other antimicrobial agents. Horizontal transfer ability was quantified using the experimental transfer assay method for low quinolone susceptibility. Further, the association between horizontal transfer ability and resistance to β-lactams, the first-choice drugs for H. influenzae infection, was investigated. The transformation efficiency of 50 clinical isolates varied widely, ranging from 10<sup>2</sup> to 10<sup>6</sup> colony forming unit (CFU) of the colonies obtained by horizontal transfer assay. Efficiency was associated with β-lactam resistance caused by ftsI mutations, indicating that strains with high horizontal transfer ability acquired quinolone low-susceptibility as well as β-lactam resistance more easily. Strains with high transformation efficiency increased the transcript level of comA, suggesting that enhanced com operon was associated with a high DNA uptake ability. Overall, this study revealed that the transformation ability of H. influenzae was associated with multiple antimicrobial resistance. Increase in the number of strains with high horizontal transformation ability has raised concerns regarding the rapid spread of antimicrobial-resistant H. influenzae.</p>","PeriodicalId":8955,"journal":{"name":"Biological & pharmaceutical bulletin","volume":" ","pages":"154-158"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50160556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perineural Treatment with High Mobility Group Box-1 Monoclonal Antibody Prevents Initiation of Pain-Like Behaviors in Female Mice with Trigeminal Neuropathy. 用高迁移率组 Box-1 单克隆抗体进行硬膜外治疗可防止三叉神经病变雌性小鼠出现类似疼痛的行为。
IF 2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.1248/bpb.b23-00729
Simeng Ma, Yoki Nakamura, Takahiro Kochi, Suzuna Uemoto, Kazue Hisaoka-Nakashima, Dengli Wang, Keyue Liu, Hidenori Wake, Masahiro Nishibori, Norimitsu Morioka

Post-traumatic trigeminal neuropathy (PTTN) is a type of chronic pain caused by damage to the trigeminal nerve. A previous study reported that pretreatment with anti-high mobility group box-1 (HMGB1) neutralizing antibodies (nAb) prevented the onset of PTTN following distal infraorbital nerve chronic constriction injury (dIoN-CCI) in male mice. Clinical evidence indicates a high incidence of PTTN in females. Although our previous study found that perineural HMGB1 is crucial in initiation of PTTN in male mice, it is currently unknown whether HMGB1 is also involved in the pathogenesis of PTTN in female mice. Therefore, in the current study, we examined the effect of anti-HMGB1 nAb on pain-like behavior in female mice following dIoN-CCI surgery. We found that dIoN-CCI surgery enhanced reactivity to mechanical and cold stimuli in female mice, which was suppressed by treatment with anti-HMGB1 nAb. Moreover, the increase in macrophages after dIoN-CCI was significantly attenuated by pretreatment with anti-HMGB1 nAb. Furthermore, anti-HMGB1 nAb treatment inhibited microglial activation in the trigeminal spinal tract nucleus. These data suggest that HMGB1 also plays a crucial role in the onset of PTTN after nerve injury in female mice. Thus, anti-HMGB1 nAb could be a novel therapeutic agent for inhibiting the onset of PTTN in female and male mice.

创伤后三叉神经病变(PTTN)是一种由三叉神经损伤引起的慢性疼痛。之前的一项研究报告称,使用抗高迁移率基团盒-1(HMGB1)中和抗体(nAb)可预防雄性小鼠在眶下神经远端慢性收缩损伤(dIoN-CCI)后发生三叉神经创伤后病变。临床证据表明,雌性小鼠的 PTTN 发病率很高。尽管我们之前的研究发现神经周围 HMGB1 在雄性小鼠 PTTN 的发病过程中起着关键作用,但目前还不清楚 HMGB1 是否也参与了雌性小鼠 PTTN 的发病过程。因此,在本研究中,我们考察了抗 HMGB1 nAb 对 dIoN-CCI 手术后雌性小鼠疼痛样行为的影响。我们发现,dIoN-CCI 手术增强了雌性小鼠对机械和冷刺激的反应性,而抗 HMGB1 nAb 治疗则抑制了这种反应性。此外,在使用抗 HMGB1 nAb 预处理后,dIoN-CCI 术后巨噬细胞的增加明显减弱。此外,抗 HMGB1 nAb 治疗可抑制三叉神经脊束核的小胶质细胞活化。这些数据表明,HMGB1 在雌性小鼠神经损伤后 PTTN 的发生中也起着至关重要的作用。因此,抗 HMGB1 nAb 可作为一种新型治疗药物,用于抑制雌性和雄性小鼠 PTTN 的发生。
{"title":"Perineural Treatment with High Mobility Group Box-1 Monoclonal Antibody Prevents Initiation of Pain-Like Behaviors in Female Mice with Trigeminal Neuropathy.","authors":"Simeng Ma, Yoki Nakamura, Takahiro Kochi, Suzuna Uemoto, Kazue Hisaoka-Nakashima, Dengli Wang, Keyue Liu, Hidenori Wake, Masahiro Nishibori, Norimitsu Morioka","doi":"10.1248/bpb.b23-00729","DOIUrl":"10.1248/bpb.b23-00729","url":null,"abstract":"<p><p>Post-traumatic trigeminal neuropathy (PTTN) is a type of chronic pain caused by damage to the trigeminal nerve. A previous study reported that pretreatment with anti-high mobility group box-1 (HMGB1) neutralizing antibodies (nAb) prevented the onset of PTTN following distal infraorbital nerve chronic constriction injury (dIoN-CCI) in male mice. Clinical evidence indicates a high incidence of PTTN in females. Although our previous study found that perineural HMGB1 is crucial in initiation of PTTN in male mice, it is currently unknown whether HMGB1 is also involved in the pathogenesis of PTTN in female mice. Therefore, in the current study, we examined the effect of anti-HMGB1 nAb on pain-like behavior in female mice following dIoN-CCI surgery. We found that dIoN-CCI surgery enhanced reactivity to mechanical and cold stimuli in female mice, which was suppressed by treatment with anti-HMGB1 nAb. Moreover, the increase in macrophages after dIoN-CCI was significantly attenuated by pretreatment with anti-HMGB1 nAb. Furthermore, anti-HMGB1 nAb treatment inhibited microglial activation in the trigeminal spinal tract nucleus. These data suggest that HMGB1 also plays a crucial role in the onset of PTTN after nerve injury in female mice. Thus, anti-HMGB1 nAb could be a novel therapeutic agent for inhibiting the onset of PTTN in female and male mice.</p>","PeriodicalId":8955,"journal":{"name":"Biological & pharmaceutical bulletin","volume":"47 1","pages":"221-226"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139511861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breed Differences in Serum Testosterone Levels of Male Pigs Are Highly Correlated with Differences in Testicular mRNA Levels of Enzymes and Proteins Involved in Testosterone Biosynthesis Process. 雄猪血清睾酮水平的品种差异与参与睾酮生物合成过程的酶和蛋白质的睾丸 mRNA 水平差异高度相关。
IF 2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.1248/bpb.b23-00679
Misaki Kojima, Jun-Ichi Suto, Masakuni Degawa

To clarify the causes of breed differences in serum testosterone levels of male pigs, which affect the mRNA expression of drug metabolizing enzymes and drug transporters in the liver and kidney, we focused on testicular enzymes and proteins involved in testosterone biosynthesis process and comparatively examined their mRNA levels by real time RT-PCR among low serum testosterone-type Landrace pigs and high serum testosterone-type Meishan and Landrace/Meishan-crossbreed (LM and ML) pigs. Testicular mRNA levels of the enzymes (3-hydroxy-3-methylglutaryl-CoA synthase 1 and 3-hydroxy-3-methylglutaryl-CoA reductase) and proteins (low density lipoprotein receptor and scavenger receptor class B member 1) affecting intracellular levels of cholesterol, a precursor of testosterone, were 2-5-fold higher in Meishan, LM and ML pigs than in Landrace pigs. Likewise, the mRNA levels of steroidogenic acute regulatory protein, which imports cholesterol to the inner mitochondrial membrane, and of testosterone biosynthesis enzymes (CYP11A1 and CYP17A1) were over 10-fold and approximately 3-fold higher, respectively, in Meishan, LM and ML pigs than in Landrace pigs. Furthermore, positive correlations between those mRNA levels and serum testosterone levels were observed. Despite large breed differences in testicular mRNA levels described above, no significant breed differences in intratesticular testosterone levels were observed. The present findings strongly suggest that breed differences in serum testosterone levels of male pigs are probably, at least in part, caused by differences in testicular mRNA levels of enzymes and proteins involved in testosterone biosynthesis process and by differences in the levels of testosterone released from testes.

为了明确公猪血清睾酮水平的品种差异影响肝脏和肾脏中药物代谢酶和药物转运体mRNA表达的原因,我们重点研究了参与睾酮生物合成过程的睾丸酶和蛋白,并通过实时RT-PCR技术比较了低血清睾酮型陆系猪和高血清睾酮型眉山猪以及陆系/眉山杂交猪(LM和ML)的mRNA水平。影响细胞内胆固醇(睾酮的前体)水平的酶(3-羟基-3-甲基戊二酰-CoA 合酶 1 和 3-羟基-3-甲基戊二酰-CoA 还原酶)和蛋白质(低密度脂蛋白受体和清道夫受体 B 类成员 1)的睾丸 mRNA 水平在眉山猪、LM 猪和 ML 猪中比在陆地猪中高 2-5 倍。同样,将胆固醇导入线粒体内膜的类固醇生成急性调节蛋白和睾酮生物合成酶(CYP11A1 和 CYP17A1)的 mRNA 水平在眉山猪、LM 猪和 ML 猪中也分别比在陆地猪中高出 10 多倍和大约 3 倍。此外,还观察到这些 mRNA 水平与血清睾酮水平呈正相关。尽管睾丸 mRNA 水平存在上述巨大的品种差异,但未观察到睾丸内睾酮水平存在显著的品种差异。本研究结果有力地表明,公猪血清睾酮水平的品种差异可能至少部分是由参与睾酮生物合成过程的酶和蛋白质的睾丸 mRNA 水平差异以及睾丸释放的睾酮水平差异造成的。
{"title":"Breed Differences in Serum Testosterone Levels of Male Pigs Are Highly Correlated with Differences in Testicular mRNA Levels of Enzymes and Proteins Involved in Testosterone Biosynthesis Process.","authors":"Misaki Kojima, Jun-Ichi Suto, Masakuni Degawa","doi":"10.1248/bpb.b23-00679","DOIUrl":"10.1248/bpb.b23-00679","url":null,"abstract":"<p><p>To clarify the causes of breed differences in serum testosterone levels of male pigs, which affect the mRNA expression of drug metabolizing enzymes and drug transporters in the liver and kidney, we focused on testicular enzymes and proteins involved in testosterone biosynthesis process and comparatively examined their mRNA levels by real time RT-PCR among low serum testosterone-type Landrace pigs and high serum testosterone-type Meishan and Landrace/Meishan-crossbreed (LM and ML) pigs. Testicular mRNA levels of the enzymes (3-hydroxy-3-methylglutaryl-CoA synthase 1 and 3-hydroxy-3-methylglutaryl-CoA reductase) and proteins (low density lipoprotein receptor and scavenger receptor class B member 1) affecting intracellular levels of cholesterol, a precursor of testosterone, were 2-5-fold higher in Meishan, LM and ML pigs than in Landrace pigs. Likewise, the mRNA levels of steroidogenic acute regulatory protein, which imports cholesterol to the inner mitochondrial membrane, and of testosterone biosynthesis enzymes (CYP11A1 and CYP17A1) were over 10-fold and approximately 3-fold higher, respectively, in Meishan, LM and ML pigs than in Landrace pigs. Furthermore, positive correlations between those mRNA levels and serum testosterone levels were observed. Despite large breed differences in testicular mRNA levels described above, no significant breed differences in intratesticular testosterone levels were observed. The present findings strongly suggest that breed differences in serum testosterone levels of male pigs are probably, at least in part, caused by differences in testicular mRNA levels of enzymes and proteins involved in testosterone biosynthesis process and by differences in the levels of testosterone released from testes.</p>","PeriodicalId":8955,"journal":{"name":"Biological & pharmaceutical bulletin","volume":"47 2","pages":"383-388"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139701734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Potential of Danyankang Capsule in High-Fat Diet-Induced Cholelithiasis and Its Impact on Liver FXR Signaling and Gut Microbiota. 丹阳康胶囊对高脂饮食诱发胆石症的治疗潜力及其对肝脏 FXR 信号转导和肠道微生物群的影响
IF 2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.1248/bpb.b24-00052
Lin Zhou, Chu-Ling Zhang, Kun Jiang, Hong-Yu Cheng, Wen-Wen Xiong, Ji-Xiao Zhu

Cholelithiasis, commonly known as gallstones, represents a prevalent hepatobiliary disorder. This study aimed to elucidate the therapeutic role and mechanism of Danyankang capsulein treating cholelithiasis induced by a high-fat diet in C57BL/6 mice. The therapeutical potential of Danyankang was assessed through biochemical analyses, histopathological examinations, protein detection, and 16S rDNA sequencing. A high-fat diet resulted in cholelithiasis manifestation in mice, with discernable abnormal serum biochemical indices and disrupted biliary cholesterol homeostasis. Danyankang treatment notably ameliorated liver inflammation symptoms and rectified serum and liver biochemical abnormalities. Concurrently, it addressed biliary imbalances. Elevated expressions of toll-like receptor 4 (TLR4), nuclear factor-kappaB (NF-κB)/pNF-κB, HMGCR, CYP7A1, and CYP8B1 observed at the inception of cholelithiasis, were notably reduced upon Danyankang administration. Furthermore, 16S rDNA analysis revealed a decline in species number and diversity of the intestinal flora in cholelithiasis-treated mice, while the decline was reversed with Danyankang treatment. Danyankang capsules reduced the abundance of Verrucomicrobiota and increased the abundance of Actinobacteriota and Proteobacteria. In conclusion, the present study demonstrates that Danyankang exerts potent therapeutic efficacy against high-fat diet-induced cholelithiasis. This beneficial outcome is potentially linked to the inhibition of the TLR4/pNF-κB and SHP/CYP7A1/CYP8B1 signaling pathways, as well as the enhancement of intestinal flora species abundance.

胆石症俗称胆结石,是一种常见的肝胆疾病。本研究旨在阐明丹阳康胶囊治疗高脂饮食诱发的 C57BL/6 小鼠胆石症的作用和机制。通过生化分析、组织病理学检查、蛋白质检测和 16S rDNA 测序评估了丹阳康的治疗潜力。高脂肪饮食导致小鼠出现胆石症,并伴有明显的血清生化指标异常和胆汁胆固醇平衡紊乱。丹阳康治疗显著改善了肝脏炎症症状,纠正了血清和肝脏生化指标异常。同时,它还能解决胆道失衡问题。服用丹阳康后,胆石症初期观察到的 toll-like receptor 4 (TLR4)、nuclear factor-kappaB (NF-κB)/pNF-κB、HMGCR、CYP7A1 和 CYP8B1 表达升高明显降低。此外,16S rDNA 分析显示,胆石症治疗小鼠肠道菌群的物种数量和多样性下降,而丹阳康治疗可逆转这种下降。丹阳康胶囊降低了Verrucomicrobiota的丰度,增加了Actinobacteriota和Proteobacteria的丰度。总之,本研究表明,丹阳康对高脂饮食引起的胆石症有很强的疗效。这种益处可能与抑制 TLR4/pNF-κB 和 SHP/CYP7A1/CYP8B1 信号通路以及提高肠道菌群物种丰富度有关。
{"title":"Therapeutic Potential of Danyankang Capsule in High-Fat Diet-Induced Cholelithiasis and Its Impact on Liver FXR Signaling and Gut Microbiota.","authors":"Lin Zhou, Chu-Ling Zhang, Kun Jiang, Hong-Yu Cheng, Wen-Wen Xiong, Ji-Xiao Zhu","doi":"10.1248/bpb.b24-00052","DOIUrl":"10.1248/bpb.b24-00052","url":null,"abstract":"<p><p>Cholelithiasis, commonly known as gallstones, represents a prevalent hepatobiliary disorder. This study aimed to elucidate the therapeutic role and mechanism of Danyankang capsulein treating cholelithiasis induced by a high-fat diet in C57BL/6 mice. The therapeutical potential of Danyankang was assessed through biochemical analyses, histopathological examinations, protein detection, and 16S rDNA sequencing. A high-fat diet resulted in cholelithiasis manifestation in mice, with discernable abnormal serum biochemical indices and disrupted biliary cholesterol homeostasis. Danyankang treatment notably ameliorated liver inflammation symptoms and rectified serum and liver biochemical abnormalities. Concurrently, it addressed biliary imbalances. Elevated expressions of toll-like receptor 4 (TLR4), nuclear factor-kappaB (NF-κB)/pNF-κB, HMGCR, CYP7A1, and CYP8B1 observed at the inception of cholelithiasis, were notably reduced upon Danyankang administration. Furthermore, 16S rDNA analysis revealed a decline in species number and diversity of the intestinal flora in cholelithiasis-treated mice, while the decline was reversed with Danyankang treatment. Danyankang capsules reduced the abundance of Verrucomicrobiota and increased the abundance of Actinobacteriota and Proteobacteria. In conclusion, the present study demonstrates that Danyankang exerts potent therapeutic efficacy against high-fat diet-induced cholelithiasis. This beneficial outcome is potentially linked to the inhibition of the TLR4/pNF-κB and SHP/CYP7A1/CYP8B1 signaling pathways, as well as the enhancement of intestinal flora species abundance.</p>","PeriodicalId":8955,"journal":{"name":"Biological & pharmaceutical bulletin","volume":"47 3","pages":"680-691"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Streamlining Considerations for Safety Measures: A Predictive Model for Addition of Clinically Significant Adverse Reactions to Japanese Drug Package Inserts. 简化安全措施的考虑因素:日本药品包装说明书中增加临床重大不良反应的预测模型。
IF 2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.1248/bpb.b23-00846
Takashi Watanabe, Kaori Ambe, Masahiro Tohkin

The addition of clinically significant adverse reactions (CSARs) to Japanese package inserts (PIs) is an important safety measure that can be used to inform medical personnel of potential health risks; however, determining the necessity of their addition can be lengthy and complex. Therefore, we aimed to construct a machine learning-based model that can predict the addition of CSARs at an early stage due to the accumulation of both Japanese and overseas adverse drug reaction (ADR) cases. The target comprised CSARs added to PIs from August 2011 to March 2022. The control group consisted of drugs without the same CSARs in their PIs by March 2022. Features were generated using ADR case accumulation data obtained from the Japanese Adverse Drug Event Report and the U.S. Food and Drug Administration Adverse Event Reporting System databases. The model was constructed using DataRobot, and its performance evaluated using the Matthews correlation coefficient. The target for the addition of CSARs included 414 cases, comprising 302 due to domestic case accumulation, 22 due to both domestic and overseas case accumulation, 12 due to overseas case accumulation, and 78 due to revisions of the company core data sheet. The best model was a generalized linear model with informative features, achieving a cross-validation of 0.8754 and a holdout of 0.8995. In conclusion, the proposed model effectively predicted CSAR additions to PIs resulting from the accumulation of ADR cases using data from both Japan and the United States.

在日本的包装说明书(PIs)中添加具有临床意义的不良反应(CSARs)是一项重要的安全措施,可用于向医务人员告知潜在的健康风险;然而,确定是否有必要添加 CSARs 可能既漫长又复杂。因此,我们的目标是构建一个基于机器学习的模型,该模型可以根据日本和海外药物不良反应(ADR)病例的积累情况,及早预测是否需要添加 CSAR。研究对象包括 2011 年 8 月至 2022 年 3 月期间添加到 PI 中的 CSAR。对照组包括在 2022 年 3 月之前其 PI 中没有相同 CSAR 的药物。利用从日本药品不良事件报告和美国食品药品管理局不良事件报告系统数据库中获得的 ADR 病例累积数据生成特征。使用 DataRobot 构建了模型,并使用马修斯相关系数对其性能进行了评估。新增 CSAR 的目标包括 414 个病例,其中 302 个是由于国内病例积累,22 个是由于国内和海外病例积累,12 个是由于海外病例积累,78 个是由于公司核心数据表的修订。最佳模型是带有信息特征的广义线性模型,交叉验证结果为 0.8754,保持率为 0.8995。总之,利用日本和美国的数据,所提出的模型可以有效地预测因 ADR 病例积累而导致 PI 增加的 CSAR。
{"title":"Streamlining Considerations for Safety Measures: A Predictive Model for Addition of Clinically Significant Adverse Reactions to Japanese Drug Package Inserts.","authors":"Takashi Watanabe, Kaori Ambe, Masahiro Tohkin","doi":"10.1248/bpb.b23-00846","DOIUrl":"10.1248/bpb.b23-00846","url":null,"abstract":"<p><p>The addition of clinically significant adverse reactions (CSARs) to Japanese package inserts (PIs) is an important safety measure that can be used to inform medical personnel of potential health risks; however, determining the necessity of their addition can be lengthy and complex. Therefore, we aimed to construct a machine learning-based model that can predict the addition of CSARs at an early stage due to the accumulation of both Japanese and overseas adverse drug reaction (ADR) cases. The target comprised CSARs added to PIs from August 2011 to March 2022. The control group consisted of drugs without the same CSARs in their PIs by March 2022. Features were generated using ADR case accumulation data obtained from the Japanese Adverse Drug Event Report and the U.S. Food and Drug Administration Adverse Event Reporting System databases. The model was constructed using DataRobot, and its performance evaluated using the Matthews correlation coefficient. The target for the addition of CSARs included 414 cases, comprising 302 due to domestic case accumulation, 22 due to both domestic and overseas case accumulation, 12 due to overseas case accumulation, and 78 due to revisions of the company core data sheet. The best model was a generalized linear model with informative features, achieving a cross-validation of 0.8754 and a holdout of 0.8995. In conclusion, the proposed model effectively predicted CSAR additions to PIs resulting from the accumulation of ADR cases using data from both Japan and the United States.</p>","PeriodicalId":8955,"journal":{"name":"Biological & pharmaceutical bulletin","volume":"47 3","pages":"611-619"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140118686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Foreword. 前言
IF 2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.1248/bpb.b24-ctf4705
Kohji Noguchi
{"title":"Foreword.","authors":"Kohji Noguchi","doi":"10.1248/bpb.b24-ctf4705","DOIUrl":"https://doi.org/10.1248/bpb.b24-ctf4705","url":null,"abstract":"","PeriodicalId":8955,"journal":{"name":"Biological & pharmaceutical bulletin","volume":"47 5","pages":"904"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140847710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sodium Orthovanadate Mitigates Nonalcoholic Fatty Liver Disease by Enhancing Autophagy. 正戊钒酸钠通过增强自噬作用缓解非酒精性脂肪肝
IF 1.7 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.1248/bpb.b24-00355
Xudong Zhang, Haiyang Zhou, Zhijun Kong, Tao Li, Chunfu Zhu, Wei Tang, Xihu Qin, Liming Tang

Sodium orthovanadate (SOV) has been investigated in recent research for its therapeutic efficacy in treating metabolic disorders. Considering the rising prevalence of non-alcoholic fatty liver disease (NAFLD), the effects of SOV on NAFLD remain to be further investigated. The aim of this study was to investigate the role and mechanism of SOV in NAFLD. Two mouse models were established by induction with high fat diet (HFD) and Western diet supplemented with the sugar in drinking water (WDS), respectively. We searched for the downstream molecules of SOV by RNA sequencing, followed by rescue experiments with an autophagy inhibitor (3-MA) in HepG2 cells as well as in animal models. The results showed that in HFD and WDS-induced NAFLD models, SOV significantly reduced body weight, inhibited lipid deposition, lowered serum triglyceride and cholesterol levels. Then RNA sequencing and RT-PCR found that the effect of SOV might be related to the activation of autophagy coregulated by hypoxia-inducible factor 1 and autophagy-related gene 5. The protective effects of SOV-activated autophagy were blocked by 3-MA, leading to the restoration of lipid deposition in vitro and in vivo. We conclude that SOV could activate liver cell autophagy, thereby improving lipid deposition and metabolism during the course of NAFLD. Our findings revealed the potential of SOV for controlling NAFLD.

最近的研究对原钒酸钠(SOV)治疗代谢紊乱的疗效进行了调查。考虑到非酒精性脂肪肝(NAFLD)发病率的上升,SOV 对非酒精性脂肪肝的影响仍有待进一步研究。本研究的目的是探讨 SOV 在非酒精性脂肪肝中的作用和机制。我们分别用高脂饮食(HFD)和添加了饮用水中糖的西式饮食(WDS)诱导建立了两种小鼠模型。我们通过 RNA 测序寻找 SOV 的下游分子,然后在 HepG2 细胞和动物模型中使用自噬抑制剂(3-MA)进行挽救实验。结果表明,在高密度脂蛋白(HFD)和低密度脂蛋白(WDS)诱导的非酒精性脂肪肝模型中,SOV能显著减轻体重、抑制脂质沉积、降低血清甘油三酯和胆固醇水平。RNA测序和RT-PCR发现,SOV的作用可能与缺氧诱导因子1和自噬相关基因5激活自噬有关。3-MA 可阻断 SOV 激活自噬的保护作用,从而恢复体外和体内的脂质沉积。我们的结论是,SOV 可激活肝细胞自噬,从而改善非酒精性脂肪肝病程中的脂质沉积和代谢。我们的研究结果揭示了 SOV 控制非酒精性脂肪肝的潜力。
{"title":"Sodium Orthovanadate Mitigates Nonalcoholic Fatty Liver Disease by Enhancing Autophagy.","authors":"Xudong Zhang, Haiyang Zhou, Zhijun Kong, Tao Li, Chunfu Zhu, Wei Tang, Xihu Qin, Liming Tang","doi":"10.1248/bpb.b24-00355","DOIUrl":"https://doi.org/10.1248/bpb.b24-00355","url":null,"abstract":"<p><p>Sodium orthovanadate (SOV) has been investigated in recent research for its therapeutic efficacy in treating metabolic disorders. Considering the rising prevalence of non-alcoholic fatty liver disease (NAFLD), the effects of SOV on NAFLD remain to be further investigated. The aim of this study was to investigate the role and mechanism of SOV in NAFLD. Two mouse models were established by induction with high fat diet (HFD) and Western diet supplemented with the sugar in drinking water (WDS), respectively. We searched for the downstream molecules of SOV by RNA sequencing, followed by rescue experiments with an autophagy inhibitor (3-MA) in HepG2 cells as well as in animal models. The results showed that in HFD and WDS-induced NAFLD models, SOV significantly reduced body weight, inhibited lipid deposition, lowered serum triglyceride and cholesterol levels. Then RNA sequencing and RT-PCR found that the effect of SOV might be related to the activation of autophagy coregulated by hypoxia-inducible factor 1 and autophagy-related gene 5. The protective effects of SOV-activated autophagy were blocked by 3-MA, leading to the restoration of lipid deposition in vitro and in vivo. We conclude that SOV could activate liver cell autophagy, thereby improving lipid deposition and metabolism during the course of NAFLD. Our findings revealed the potential of SOV for controlling NAFLD.</p>","PeriodicalId":8955,"journal":{"name":"Biological & pharmaceutical bulletin","volume":"47 10","pages":"1786-1795"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Physiological and Pathological Significance of Chloride Channels. 氯离子通道的生理和病理意义。
IF 2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.1248/bpb.b23-00820
Hisao Yamamura

Cl- influx and efflux through Cl- channels play a role in regulating the homeostasis of biological functions. Therefore, the hyperfunction or dysfunction of Cl- channels elicits pathological mechanisms. The Cl- channel superfamily includes voltage-gated Cl- (ClC) channels, Ca2+-activated Cl- channels (ClCa; TMEM16A/TMEM16B), cystic fibrosis transmembrane conductance regulator channels, and ligand-gated Cl- channels. These channels are ubiquitously expressed to regulate ion homeostasis, muscle tonus, membrane excitability, cell volume, survival, neurotransmission, and transepithelial transport. The activation or inhibition of Cl- channels changes the membrane potential, thereby affecting cytosolic Ca2+ signals. An elevation in cytosolic [Ca2+] triggers physiological and pathological responses in most cells. However, the roles of Cl- channels have not yet been examined as extensively as cation (Na+, Ca2+, and K+) channels. We recently reported the functional expression of: (i) TMEM16A/ClCa channels in portal vein and pulmonary arterial smooth muscle cells (PASMC), pinealocytes, and brain capillary endothelial cells; (ii) TMEM16B/ClCa channels in pinealocytes; (iii) ClC-3 channels in PASMC and chondrocytes; and (iv) ClC-7 channels in chondrocytes. We also showed that the down-regulation of TMEM16A and ClC-7 channel expression was associated with cirrhotic portal hypertension and osteoarthritis, respectively, whereas the enhanced expression of TMEM16A and ClC-3 channels was involved in the pathogenesis of cerebral ischemia and pulmonary arterial hypertension, respectively. Further investigations on the physiological/pathological functions of Cl- channels will provide insights into biological functions and contribute to the screening of novel target(s) of drug discovery for associated diseases.

通过 Cl- 通道的 Cl- 流入和流出在调节生物功能的平衡方面发挥作用。因此,Cl-通道功能亢进或失调会引发病理机制。Cl-通道超家族包括电压门控Cl-(ClC)通道、Ca2+激活Cl-通道(ClCa;TMEM16A/TMEM16B)、囊性纤维化跨膜传导调节器通道和配体门控Cl-通道。这些通道普遍表达,用于调节离子平衡、肌肉张力、膜兴奋性、细胞体积、存活、神经传递和跨上皮细胞转运。Cl- 通道的激活或抑制会改变膜电位,从而影响细胞膜 Ca2+ 信号。细胞膜[Ca2+]的升高会引发大多数细胞的生理和病理反应。然而,人们尚未像研究阳离子(Na+、Ca2+ 和 K+)通道那样广泛地研究 Cl- 通道的作用。最近,我们报道了(i) 门静脉和肺动脉平滑肌细胞(PASMC)、松果体细胞和脑毛细血管内皮细胞中的 TMEM16A/ClCa 通道;(ii) 松果体细胞中的 TMEM16B/ClCa 通道;(iii) PASMC 和软骨细胞中的 ClC-3 通道;以及 (iv) 软骨细胞中的 ClC-7 通道。我们还发现,TMEM16A 和 ClC-7 通道表达的下调分别与肝硬化门脉高压和骨关节炎有关,而 TMEM16A 和 ClC-3 通道表达的增强则分别与脑缺血和肺动脉高压的发病机制有关。对Cl-通道生理/病理功能的进一步研究将有助于深入了解其生物学功能,并有助于筛选相关疾病的新药靶点。
{"title":"Physiological and Pathological Significance of Chloride Channels.","authors":"Hisao Yamamura","doi":"10.1248/bpb.b23-00820","DOIUrl":"10.1248/bpb.b23-00820","url":null,"abstract":"<p><p>Cl<sup>-</sup> influx and efflux through Cl<sup>-</sup> channels play a role in regulating the homeostasis of biological functions. Therefore, the hyperfunction or dysfunction of Cl<sup>-</sup> channels elicits pathological mechanisms. The Cl<sup>-</sup> channel superfamily includes voltage-gated Cl<sup>-</sup> (ClC) channels, Ca<sup>2+</sup>-activated Cl<sup>-</sup> channels (Cl<sub>Ca</sub>; TMEM16A/TMEM16B), cystic fibrosis transmembrane conductance regulator channels, and ligand-gated Cl<sup>-</sup> channels. These channels are ubiquitously expressed to regulate ion homeostasis, muscle tonus, membrane excitability, cell volume, survival, neurotransmission, and transepithelial transport. The activation or inhibition of Cl<sup>-</sup> channels changes the membrane potential, thereby affecting cytosolic Ca<sup>2+</sup> signals. An elevation in cytosolic [Ca<sup>2+</sup>] triggers physiological and pathological responses in most cells. However, the roles of Cl<sup>-</sup> channels have not yet been examined as extensively as cation (Na<sup>+</sup>, Ca<sup>2+</sup>, and K<sup>+</sup>) channels. We recently reported the functional expression of: (i) TMEM16A/Cl<sub>Ca</sub> channels in portal vein and pulmonary arterial smooth muscle cells (PASMC), pinealocytes, and brain capillary endothelial cells; (ii) TMEM16B/Cl<sub>Ca</sub> channels in pinealocytes; (iii) ClC-3 channels in PASMC and chondrocytes; and (iv) ClC-7 channels in chondrocytes. We also showed that the down-regulation of TMEM16A and ClC-7 channel expression was associated with cirrhotic portal hypertension and osteoarthritis, respectively, whereas the enhanced expression of TMEM16A and ClC-3 channels was involved in the pathogenesis of cerebral ischemia and pulmonary arterial hypertension, respectively. Further investigations on the physiological/pathological functions of Cl<sup>-</sup> channels will provide insights into biological functions and contribute to the screening of novel target(s) of drug discovery for associated diseases.</p>","PeriodicalId":8955,"journal":{"name":"Biological & pharmaceutical bulletin","volume":"47 1","pages":"1-13"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139085730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vildagliptin Treatment Ameliorates Renal Interstitial Fibrosis in a Murine Model of Unilateral Ureteral Obstruction. 维达列汀治疗可改善单侧输尿管阻塞小鼠模型的肾间质纤维化
IF 2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.1248/bpb.b23-00609
Shigeyoshi Honma, Sota Kakuage, Yuta Morita, Takeki Ito, Makoto Yoshida

Renal interstitial fibrosis in mice can be modeled using unilateral ureteral obstruction (UUO). Here, we investigated the anti-fibrotic effects of the dipeptidyl peptidase-4 inhibitor vildagliptin in this model. We found that vildagliptin given in the drinking water at 10.6 ± 1.5 mg/kg/d prevented fibrosis. Mechanistically, UUO was associated with extracellular signal-regulated kinase (ERK) phosphorylation and with the accumulation of the toxic lipid peroxidation product expression of 4-hydroxy-2-nonenal (4-HNE). Both were significantly inhibited by vildagliptin. Similarly, UUO caused reductions in heme oxygenase-1 (HO-1) mRNA in the kidney, whereas interleukin-6 (IL-6) and cyclooxygenase-1 (COX-1) mRNA were increased; these effects were also prevented by vildagliptin. Taking these data together, we propose that vildagliptin reduces renal interstitial fibrosis resulting from UUO by means of its effects on ERK phosphorylation and the amounts of 4-HNE, HO-1, IL-6 and COX-1 in the kidney.

小鼠肾间质纤维化可通过单侧输尿管梗阻(UUO)来模拟。在此,我们研究了二肽基肽酶-4抑制剂维达列汀在该模型中的抗纤维化作用。我们发现,以 10.6 ± 1.5 mg/kg/d 的剂量在饮用水中添加维达列汀可预防纤维化。从机理上讲,UUO与细胞外信号调节激酶(ERK)磷酸化和有毒脂质过氧化产物4-羟基-2-壬烯醛(4-HNE)的积累有关。维达列汀对这两种情况都有明显的抑制作用。同样,UUO 导致肾脏中血红素加氧酶-1(HO-1)mRNA 减少,而白细胞介素-6(IL-6)和环氧化酶-1(COX-1)mRNA 增加;这些影响也被维达列汀所阻止。综合这些数据,我们认为维达列汀通过影响ERK磷酸化以及肾脏中4-HNE、HO-1、IL-6和COX-1的含量,减轻了UUO导致的肾间质纤维化。
{"title":"Vildagliptin Treatment Ameliorates Renal Interstitial Fibrosis in a Murine Model of Unilateral Ureteral Obstruction.","authors":"Shigeyoshi Honma, Sota Kakuage, Yuta Morita, Takeki Ito, Makoto Yoshida","doi":"10.1248/bpb.b23-00609","DOIUrl":"10.1248/bpb.b23-00609","url":null,"abstract":"<p><p>Renal interstitial fibrosis in mice can be modeled using unilateral ureteral obstruction (UUO). Here, we investigated the anti-fibrotic effects of the dipeptidyl peptidase-4 inhibitor vildagliptin in this model. We found that vildagliptin given in the drinking water at 10.6 ± 1.5 mg/kg/d prevented fibrosis. Mechanistically, UUO was associated with extracellular signal-regulated kinase (ERK) phosphorylation and with the accumulation of the toxic lipid peroxidation product expression of 4-hydroxy-2-nonenal (4-HNE). Both were significantly inhibited by vildagliptin. Similarly, UUO caused reductions in heme oxygenase-1 (HO-1) mRNA in the kidney, whereas interleukin-6 (IL-6) and cyclooxygenase-1 (COX-1) mRNA were increased; these effects were also prevented by vildagliptin. Taking these data together, we propose that vildagliptin reduces renal interstitial fibrosis resulting from UUO by means of its effects on ERK phosphorylation and the amounts of 4-HNE, HO-1, IL-6 and COX-1 in the kidney.</p>","PeriodicalId":8955,"journal":{"name":"Biological & pharmaceutical bulletin","volume":"47 1","pages":"37-42"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139085735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-atrial Fibrillatory and Cardiorenal Protective Effects of the Combination of Valsartan and Cilnidipine in Dahl Salt-Sensitive Rats. 缬沙坦和西尼地平复方制剂对达尔盐敏感大鼠抗心房颤动和心力衰竭的保护作用
IF 1.7 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.1248/bpb.b24-00265
Eri Harada, Kazumi Sugino, Akira Takahara

The current study aimed to investigate the anti-atrial fibrillatory (AF) effects of a combination of valsartan and a calcium channel blocker (cilnidipine or amlodipine) in Dahl salt-sensitive (Dahl S) rats. Seven-week-old male Dahl S rats were fed an 8% salt diet. Six weeks later, valsartan (60 mg/kg, Val group), cilnidipine + valsartan (10 + 60 mg/kg, CV group), amlodipine + valsartan (3 + 60 mg/kg, AV group), or vehicle was orally administered daily for 5 weeks. Echocardiography and atrial electrophysiological evaluations were performed on the last day of treatment. Blood pressure in each drug treatment group was lower than in the Vehicle group. The duration of AF induced by atrial burst stimulation was shorter in the Val group (3.2 ± 1.6 s) than in the Vehicle group (11.2 ± 6.0 s), which was further shortened in the CV and AV groups (1.1 ± 0.3 and 1.3 ± 0.3 s, respectively). Left ventricular ejection fraction and left ventricular fractional shortening were greater in the CV and AV groups than those in the Vehicle group. Urinary albumin excretion in the CV group was the lowest among the drug-treated groups. The results collectively suggest that the combination of a calcium channel blocker with valsartan could be useful in terms of its anti-AF action as well as for improving cardiac and renal functions.

本研究旨在探讨缬沙坦和钙通道阻滞剂(西尼地平或氨氯地平)联合使用对盐敏感(Dahl S)大鼠的抗心房颤动(AF)作用。给七周大的雄性 Dahl S 大鼠喂食含盐量为 8%的食物。六周后,每天口服缬沙坦(60 毫克/千克,Val 组)、西尼地平 + 缬沙坦(10 + 60 毫克/千克,CV 组)、氨氯地平 + 缬沙坦(3 + 60 毫克/千克,AV 组)或药物,持续 5 周。在治疗的最后一天进行超声心动图和心房电生理评估。各药物治疗组的血压均低于车辆组。Val 组心房爆发刺激诱发房颤的持续时间(3.2 ± 1.6 秒)短于车辆组(11.2 ± 6.0 秒),CV 组和 AV 组的持续时间进一步缩短(分别为 1.1 ± 0.3 秒和 1.3 ± 0.3 秒)。与车辆组相比,CV 组和 AV 组的左心室射血分数和左心室缩短率更高。在药物治疗组中,CV 组的尿白蛋白排泄量最低。这些结果共同表明,钙通道阻滞剂与缬沙坦的联合用药不仅能起到抗心房颤动的作用,还能改善心功能和肾功能。
{"title":"Anti-atrial Fibrillatory and Cardiorenal Protective Effects of the Combination of Valsartan and Cilnidipine in Dahl Salt-Sensitive Rats.","authors":"Eri Harada, Kazumi Sugino, Akira Takahara","doi":"10.1248/bpb.b24-00265","DOIUrl":"https://doi.org/10.1248/bpb.b24-00265","url":null,"abstract":"<p><p>The current study aimed to investigate the anti-atrial fibrillatory (AF) effects of a combination of valsartan and a calcium channel blocker (cilnidipine or amlodipine) in Dahl salt-sensitive (Dahl S) rats. Seven-week-old male Dahl S rats were fed an 8% salt diet. Six weeks later, valsartan (60 mg/kg, Val group), cilnidipine + valsartan (10 + 60 mg/kg, CV group), amlodipine + valsartan (3 + 60 mg/kg, AV group), or vehicle was orally administered daily for 5 weeks. Echocardiography and atrial electrophysiological evaluations were performed on the last day of treatment. Blood pressure in each drug treatment group was lower than in the Vehicle group. The duration of AF induced by atrial burst stimulation was shorter in the Val group (3.2 ± 1.6 s) than in the Vehicle group (11.2 ± 6.0 s), which was further shortened in the CV and AV groups (1.1 ± 0.3 and 1.3 ± 0.3 s, respectively). Left ventricular ejection fraction and left ventricular fractional shortening were greater in the CV and AV groups than those in the Vehicle group. Urinary albumin excretion in the CV group was the lowest among the drug-treated groups. The results collectively suggest that the combination of a calcium channel blocker with valsartan could be useful in terms of its anti-AF action as well as for improving cardiac and renal functions.</p>","PeriodicalId":8955,"journal":{"name":"Biological & pharmaceutical bulletin","volume":"47 7","pages":"1360-1367"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141858949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Biological & pharmaceutical bulletin
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1